<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prothrombin complex concentrate, 3-factor, unactivated, from human plasma: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prothrombin complex concentrate, 3-factor, unactivated, from human plasma: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Prothrombin complex concentrate, 3-factor, unactivated, from human plasma: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10085" href="/d/html/10085.html" rel="external">see "Prothrombin complex concentrate, 3-factor, unactivated, from human plasma: Drug information"</a> and <a class="drug drug_patient" data-topicid="11490" href="/d/html/11490.html" rel="external">see "Prothrombin complex concentrate, 3-factor, unactivated, from human plasma: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F169679"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Profilnine</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1052661"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antihemophilic Agent</span>;</li>
<li>
<span class="list-set-name">Blood Product Derivative</span></li></ul></div>
<div class="block dop drugH1Div" id="F169686"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Bebulin has been discontinued in the US for &gt;1 year.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d3c8dbc-ec3d-4b92-8b0e-9f550b04753f">Hemophilia B</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemophilia B:</b> Children and Adolescents: IV: Dosage is expressed in units of factor IX activity and must be individualized based on severity of factor IX deficiency, extent and location of bleeding, and clinical status of patient (WHF 2013). When multiple doses are required, administer at 24-hour intervals unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Formula for units required to raise blood level %:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Bebulin VH: In general, 1 unit/kg of factor IX will increase the plasma factor IX level by 0.8%.</p>
<p style="text-indent:-2em;margin-left:8em;">Number of Factor IX units required = body weight (kg) x desired factor IX increase (as % of normal) x 1.2 units/kg</p>
<p style="text-indent:-2em;margin-left:10em;">For example, to increase factor IX level to 25% of normal in a 70 kg patient: Number of factor IX units needed = 70 kg x 25 x 1.2 unit/kg = 2100 units</p>
<p style="text-indent:-2em;margin-left:6em;">Profilnine SD: In general, 1 unit/kg of factor IX will increase the plasma factor IX level by 1%:</p>
<p style="text-indent:-2em;margin-left:8em;">Number of factor IX units required = bodyweight (kg) x desired factor IX increase (as % of normal) x 1 unit/kg</p>
<p style="text-indent:-2em;margin-left:10em;">For example, to increase factor IX level to 25% of normal in a 70 kg patient: Number of factor IX units needed = 70 kg x 25 x 1 unit/kg = 1750 units</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>As a general rule, the level of factor IX required for treatment of different conditions is listed below: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Hemorrhage: </b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Minor bleeding (early hemarthrosis, minor epistaxis, gingival bleeding, mild hematuria):</i></p>
<p style="text-indent:-2em;margin-left:10em;">Bebulin VH: Raise factor IX level to 20% of normal [typical initial dose: 25 to 35 units/kg]; generally a single dose is sufficient.</p>
<p style="text-indent:-2em;margin-left:10em;">Profilnine SD: Mild to moderate bleeding: Raise factor IX level to 20% to 30% of normal; generally a single dose is sufficient.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Moderate bleeding (severe joint bleeding, early hematoma, major open bleeding, minor trauma, minor hemoptysis, hematemesis, melena, major hematuria):</i></p>
<p style="text-indent:-2em;margin-left:10em;">Bebulin VH: Raise factor IX level to 40% of normal [typical initial dose: 40-55 units/kg]; average duration of treatment is 2 days or until adequate wound healing.</p>
<p style="text-indent:-2em;margin-left:10em;">Profilnine SD: Mild to moderate bleeding: Raise factor IX level to 20% to 30% of normal.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Major bleeding (severe hematoma, major trauma, severe hemoptysis, hematemesis, melena):</i></p>
<p style="text-indent:-2em;margin-left:10em;">Bebulin VH: Raise factor IX level to ≥60% of normal [typical initial dose: 60 to 70 units/kg]; average duration of treatment is 2 to 3 days or until adequate wound healing. Do not raise &gt;60% in patients who may be predisposed to thrombosis.</p>
<p style="text-indent:-2em;margin-left:10em;">Profilnine SD: Raise factor IX level to 30% to 50% of normal; daily infusions are usually required.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Surgical procedures:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Dental surgery:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Bebulin VH: Raise factor IX level to 40% to 60% of normal on day of surgery [typical dose: 50 to 60 units/kg]. One infusion, administered 1 hour prior to surgery, is generally sufficient for the extraction of one tooth; for the extraction of multiple teeth, replacement therapy may be required for up to 1 week (see dosing guidelines for Minor Surgery).</p>
<p style="text-indent:-2em;margin-left:10em;">Profilnine SD: Raise factor IX level to 50% of normal immediately prior to procedure; administer additional doses if bleeding recurs.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Minor surgery:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Bebulin VH: Raise factor IX level to 40% to 60% of normal on day of surgery [typical initial dose: 50 to 60 units/kg]. Decrease factor IX level from 40% of normal to 20% of normal during initial postoperative period (1 to 2 weeks or until adequate wound healing) [typical dose: 55 units/kg decreasing to 25 units/kg]. The preoperative dose should be given 1 hour prior to surgery. The average dosing interval may be every 12 hours initially, then every 24 hours later in the postoperative period.</p>
<p style="text-indent:-2em;margin-left:10em;">Profilnine SD: Raise factor IX level to 30% to 50% of normal for at least 1 week following surgery.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Major surgery:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Bebulin VH: Raise factor IX level to ≥60% of normal on day of surgery [typical initial dose: 70 to 95 units/kg]; do not raise &gt;60% in patients who may be predisposed to thrombosis. Decrease factor IX level from 60% of normal to 20% of normal during initial postoperative period (1-2 weeks) [typical dose: 70 units/kg decreasing to 35 units/kg]; further decrease to maintain a factor IX level of 20% of normal during late postoperative period (≥3 weeks) and continuing until adequate wound healing is achieved [typical dose: 35 units/kg decreasing to 25 units/kg]. The preoperative dose should be given 1 hour prior to surgery. The average dosing interval may be every 12 hours initially, then every 24 hours later in the postoperative period.</p>
<p style="text-indent:-2em;margin-left:10em;">Profilnine SD: Raise factor IX level to 30% to 50% of normal for at least 1 week following surgery.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Prophylaxis, hemorrhage (long-term management):</b> Bebulin VH: 20 to 30 units/kg/dose once or twice a week may reduce frequency of spontaneous hemorrhage; dosing regimen should be individualized.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51109808"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block dohp drugH1Div" id="F51109809"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; monitor factor IX levels. Use with caution due to the risk of thromboembolic complications.</p></div>
<div class="block doa drugH1Div" id="F169681"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10085" href="/d/html/10085.html" rel="external">see "Prothrombin complex concentrate, 3-factor, unactivated, from human plasma: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="98495059-e110-44f0-ad91-ba0bd4d84e5d">Hemophilia B, without inhibitors</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemophilia B, without inhibitors:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: Factor IX complex (Human) [Factors II, IX, X] (Profilnine) contains low or nontherapeutic levels of factor VII component</b> and should not be confused with Prothrombin Complex Concentrate (Human) [(Factors II, VII, IX, X), Protein C, Protein S] (Kcentra, Octaplex) which contains therapeutic levels of factor VII.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Treatment and control of bleeding episodes or perioperative management:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Intermittent IV bolus dosing</i>: IV: </b>Utilize steps 1 to 4 to determine intermittent bolus dosing strategy. Individualize dosage based on coagulation studies performed prior to treatment and at regular intervals during treatment.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Step 1:</b> Identify product-specific in vivo recovery (IVR) for dosing calculations (<b>Note:</b> IVR indicates the expected increase in factor IX level, which occurs with 1 unit/kg of factor IX product administration):</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Profilnine/Profilnine SD IVR:</i> 1.15.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Step 2:</b> Determine desired factor IX peak level and anticipated duration of therapy based on the World Federation of Hemophilia (WFH) treatment recommendations; see table. Selection of the lower-dose practice pattern requires closer observation with the potential for requiring escalation to higher doses based on clinical response.</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption>
<b>Factor IX Complex (Human) [Factors II, IX, X] WFH<sup>a</sup> Treatment Recommendations</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Type of hemorrhage or surgery</p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;text-align:left;">Lower-dose practice pattern</p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;text-align:left;">Higher-dose practice pattern</p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">Desired peak factor IX level (units/dL)</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Treatment duration (days)</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Desired peak factor IX level (units/dL)</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Treatment duration (days)</p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;">
<sup>a </sup>WFH = World Hemophilia Federation; (WFH [Srivastava 2020]).</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;">
<sup>b </sup>May be longer if response is inadequate.</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;">
<sup>c</sup> A single dose may be sufficient for some joint bleeds; determine need for additional doses based on clinical response.</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>d </sup>Sometimes longer as secondary prophylaxis during physical therapy.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Joint</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2<sup>b,c</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2<sup>b,c</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Superficial muscle/no neurovascular compromise (except iliopsoas)</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 to 3<sup>b</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 to 3<sup>b</sup></p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Iliopsoas or deep muscle with neurovascular injury or substantial blood loss</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15 to 30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5<sup>d</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5<sup>d</sup></p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Intracranial</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 7</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 to 21</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 to 14</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Throat and neck</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 7</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 to 14</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>GI</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7 to 14</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Renal</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15 to 30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Deep laceration</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15 to 30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 to 7</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Surgery (major)</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Pre-op</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 to 70</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:left;">Post-op</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 6</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 6</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7 to 14</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7 to 14</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Surgery (minor)</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Pre-op</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 80</p></td>
<td align="center"></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 to 80</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Post-op</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 5</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 5</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">
<b>Step 3:</b> Calculate dose using IVR from step 1, desired peak factor IX level from step 2, and the following equation:</p>
<p style="text-indent:-2em;margin-left:8em;">Factor IX units required = [(desired peak factor IX level − patient's baseline factor IX level) × body weight (kg)] / IVR</p>
<p style="text-indent:-2em;margin-left:10em;">(<b>Note:</b> Factor IX units are in units/dL.)</p>
<p style="text-indent:-2em;margin-left:8em;">Example (Profilnine) for 50 kg patient with desired peak factor IX level of 35 units/dL, baseline factor IX level of 5 units/dL, IVR = 1.15:</p>
<p style="text-indent:-2em;margin-left:10em;">Factor IX units required = [(35 units/dL − 5 units/dL) × 50 kg)] ⁄ 1.15 = 1,304 units factor IX</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Step 4:</b> Determine need for repeat dosing based on manufacturer’s recommended frequency of repeat dosing.<b> Note:</b> Frequency of administration must also take into consideration subsequent factor IX activity measurements and clinical response.</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption>
<b>Factor IX Complex (Human) [Factors II, IX, X] Administration Frequency According to Clinical Scenario</b></caption>
<colgroup><col align="center"/>
<col/>
<col/>
<col/>
<col/>
<col/>
</colgroup><thead>
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;">Product</p></th>
<th align="left" colspan="3">
<p style="text-indent:0em;">Bleeding event</p></th>
<th align="left" colspan="2">
<p style="text-indent:0em;">Surgery</p></th></tr>
<tr>
<th align="left">
<p style="text-indent:0em;">Minor severity</p></th>
<th align="left">
<p style="text-indent:0em;">Moderate severity</p></th>
<th align="left">
<p style="text-indent:0em;">Major severity</p></th>
<th align="left">
<p style="text-indent:0em;">Minor bleeding risk</p></th>
<th align="left">
<p style="text-indent:0em;">Major bleeding risk</p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Profilnine</p></td>
<td align="left">
<p style="text-indent:0em;">Every 16 to 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;">Every 16 to 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;">Every 16 to 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;">Every 16 to 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;">Every 16 to 24 hours</p></td></tr></tbody></table></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1933b7fc-bcd4-44c6-8b09-6ab219ffe885">Life-threatening hemorrhage associated with warfarin</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Life-threatening hemorrhage associated with warfarin (off-label use):</b> IV: <b>Note:</b> Products contain low or nontherapeutic levels of factor VII component; therefore, additional fresh frozen plasma (FFP) or factor VIIa may be considered (Masotti 2011). When immediate INR reversal is required, concomitant use of 1 to 2 units of FFP should be considered to ensure acute INR reversal (Baker 2004; Holland 2009). Coadminister vitamin K (phytonadione) 5 to 10 mg by slow IV infusion (ACCP [Guyatt 2012]); vitamin K may be repeated every 12 hours if INR is persistently elevated. Factor IX complex (human) dosing has not been established in this setting; the following regimens have been used with some success.</p>
<p style="text-indent:-2em;margin-left:4em;">The following 2 methods have been suggested, but are not product specific:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Adjusted-dose regimen, weight based (Liumbruno 2009):</i></p>
<p style="text-indent:-2em;margin-left:6em;">INR &lt;2: 20 units/kg</p>
<p style="text-indent:-2em;margin-left:6em;">INR 2 to 4: 30 units/kg</p>
<p style="text-indent:-2em;margin-left:6em;">INR &gt;4: 50 units/kg</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> If after administration, INR remains &gt;1.5 consider repeating dose appropriate for INR.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>May also determine dose based on presenting INR and estimated functional prothrombin complex (PC) expressed as percentage of normal plasma levels (see table; Masotti 2011):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Units needed to be infused = (<b>target</b> % of functional PC to be reached – <b>current</b> estimated % of functional PC) x kg of body weight</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Example:</b></p>
<p style="text-indent:-2em;margin-left:8em;">Patient (weight: 70 kg) presents with INR of 4.5 which corresponds to an <b>estimated % functional PC</b> of 10% (see table). Target INR of 1.4 corresponds to an <b>estimated target % functional PC</b> of 40%.</p>
<p style="text-indent:-2em;margin-left:8em;">Units needed to be infused = (40 - 10) x 70 kg = 2,100 units</p>
<table border="1" data-table-id="FactorIXCom" frame="border" rules="all" style="margin-left:6em;">
<caption>
<b>Conversion of the INR to Estimated Functional Prothrombin Complex (PC)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center" valign="middle">
<p style="text-indent:0em;">INR Value</p></th>
<th align="center" valign="middle">
<p style="text-indent:0em;">Estimated</p>
<p style="text-indent:0em;">Functional PC</p></th></tr></thead>
<tbody>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">≥5</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">5%</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">4 to 4.9</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">10%</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">2.6 to 3.2</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">15%</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">2.2 to 2.5</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">20%</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">1.9 to 2.1</p></td>
<td align="center">
<p style="text-indent:0em;">25%</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">1.7 to 1.8</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">30%</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">1.4 to 1.6</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">40%</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">1 to 1.3</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">100%</p></td></tr></tbody></table></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1b48d887-19da-4b53-af6b-a05f1018bf49">Intracranial hemorrhage associated with warfarin</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Intracranial hemorrhage associated with warfarin (off-label use):</b> IV: <b>Note:</b> Factor IX complex (human) products contain low or nontherapeutic levels of factor VII component (ie, considered a 3-factor PCC). Four-factor PCC is preferred. Administer with vitamin K IV (NCS/SCCM [Frontera 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Fixed-dose regimen, weight based: </i>INR ≥1.4: 50 units/kg; repeat INR within 15 to 60 minutes and serially every 6 to 8 hours for the next 24 to 48 hours. If INR remains ≥1.4 within the first 24 to 48 hours after initial dose, use FFP (alone) for further correction. For initial reversal, it is suggested to administer factor IX complex (PCC) alone rather than combined with FFP or recombinant factor VIIa (NCS/SCCM [Frontera 2016]).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990485"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50987769"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; monitor factor IX levels. Use with caution due to the risk of thromboembolic complications.</p></div>
<div class="block adr drugH1Div" id="F169661"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Flushing, thrombosis (sometimes fatal)</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Chills, drowsiness, headache, lethargy, paresthesia</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Disseminated intravascular coagulation, heparin-induced thrombocytopenia (with products containing heparin)</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Anaphylactic shock</p>
<p style="text-indent:-2em;margin-left:2em;">Immunologic: Antibody development (to clotting factor)</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Dyspnea</p>
<p style="text-indent:-2em;margin-left:2em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F169674"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F169658"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antibody formation: The development of factor IX antibodies (or inhibitors) has been reported with factor IX therapy (usually occurs within the first 10 to 20 exposure days); the risk of severe hypersensitivity reactions occurring may be greater in these patients. When clinical response is suboptimal, the patient has reached a specified number of exposure days, or patient is to undergo surgical procedure, screen for inhibitors. Patients with severe hemophilia compared to those with mild or moderate hemophilia are more likely to develop inhibitors (WFH [Srivastava 2013]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity and anaphylactic/anaphylactoid reactions have been reported with use. Delayed reactions (up to 20 days after infusion) in previously untreated patients may also occur. Due to potential for allergic reactions, the initial ~10 to 20 administrations should be performed under appropriate medical supervision. Hypersensitivity reactions may be associated with factor IX inhibitor development; patients experiencing allergic reactions should be evaluated for factor IX inhibitors. If severe hypersensitivity reactions occur, consider the use of alternative hemostatic measures (WFH [Srivastava 2013]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombotic events: Thrombotic events (eg, deep vein thrombosis, pulmonary embolism, thrombotic strokes) as well as disseminated intravascular coagulation (DIC) have occurred. Monitor closely for signs or symptoms of intravascular coagulation or thrombosis; risk is higher in patients with congenital or acquired coagulation disorders, and with repeated dosing or high doses. Use with caution when administering to patients with liver disease, history of coronary artery disease, pre- or postoperatively, neonates, or patients at risk of thromboembolic phenomena, disseminated intravascular coagulation or patients with signs of fibrinolysis due to the potential risk of thromboembolic complications. Discontinue infusion immediately if signs or symptoms of thrombosis or embolism occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with extreme caution in patients with hepatic impairment due to the risk of thromboembolic complications.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Human plasma: Product of human plasma; may potentially contain infectious agents that could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p>
<p style="text-indent:-2em;margin-left:4em;">• Latex: Some product packaging may contain natural rubber latex.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: <b>Factor IX Complex (Human) [Factors II, IX, X] (Profilnine) contains low or nontherapeutic levels of factor VII component </b>and should not be confused with Prothrombin complex concentrate (Human) [(Factors II, VII, IX, X), Protein C, Protein S] (Kcentra, Octaplex) which contains therapeutic levels of factor VII. Factor IX Complex (Human) [Factors II, IX, X] (Profilnine) should not be used for the treatment of factor VII deficiency. When treating warfarin-associated hemorrhage (off-label use), administration of additional fresh frozen plasma (FFP) or factor VIIa should be considered.</p>
<p style="text-indent:-2em;margin-left:4em;">• Clinical response: Response to factor IX administration may vary. If bleeding is not controlled with the recommended dose, determine plasma level of factor IX and follow with a sufficient dose to achieve satisfactory clinical response. If plasma levels of factor IX fail to increase as expected or bleeding continues, suspect the presence of an inhibitor; test as appropriate.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immune tolerance induction: Safety and efficacy have not been established in immune tolerance induction with factor IX products. Nephrotic syndrome has occurred following immune tolerance induction in patients with hemophilia B with factor IX inhibitors receiving factor IX products.</p></div>
<div class="block dosfc drugH1Div" id="F25573582"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Strengths expressed as an approximate value. Consult individual vial labels for exact potency within each vial.</p></div>
<div class="block foc drugH1Div" id="F169668"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Profilnine: 500 units (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Profilnine: 500 units (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Profilnine: 1000 units (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Profilnine: 1000 units (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Profilnine: 1500 units (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Profilnine: 1500 units (1 ea) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F169654"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F21121619"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Profilnine Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 unit (Price provided is per AHF Unit): $1.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 unit (Price provided is per AHF Unit): $1.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1500 unit (Price provided is per AHF Unit): $1.78</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52612801"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV administration only. Visually inspect for particulate matter and discoloration prior to administration whenever permitted by solution or container.  Infuse slowly; rate of administration should be individualized for patient's comfort; rapid IV administration may cause vasomotor reactions; maximum rates of administration: Bebulin VH: 2 mL/minute; Profilnine SD: 10 mL/minute; <b>Note:</b> Slowing the rate of infusion, changing the lot of medication, or administering antihistamines may relieve some adverse reactions. </p></div>
<div class="block adm drugH1Div" id="F169671"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Solution should be infused at room temperature. Rate should not exceed 10 mL/minute. Vasomotor reactions may result from rapid administration; do not exceed the recommended infusion rates. Slowing the rate of infusion, changing the lot of medication, or administering antihistamines may relieve some adverse reactions.</p></div>
<div class="block sts drugH1Div" id="F169678"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Storage temperature should not exceed 25°C (77°F); do not freeze.</p></div>
<div class="block usep drugH1Div" id="F53566857"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Prevention and control of bleeding in patients with factor IX deficiency (hemophilia B or Christmas disease) (Profilnine® SD: FDA approved in ages &gt;16 years and adults; Bebulin® VH: FDA approved in adults)</p></div>
<div class="block mst drugH1Div" id="F14634078"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Factor IX Complex may be confused with Factor IX</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Safety concern:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Factor IX Complex may be confused with Factor IX</p>
<p style="text-indent:-2em;margin-left:4em;">The term “Prothrombin Complex Concentrate” or “PCC” has been used to describe both Factor IX Complex (Human) [Factors II, IX, X] and Prothrombin Complex Concentrate (Human) [(Factors II, VII, IX, X), Protein C, Protein S]. <b>Factor IX Complex (Human) [Factors II, IX, X] (Profilnine) contains low or nontherapeutic levels of factor VII component </b>and should not be confused with Prothrombin Complex Concentrate (Human) [(Factors II, VII, IX, X), Protein C, Protein S] (Kcentra, Octaplex) which contains therapeutic levels of factor VII.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299308"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F169663"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antifibrinolytic Agents: May enhance the adverse/toxic effect of Factor IX Complex (Human) [(Factors II, IX, X)]. Specifically, the risk for thrombosis may be increased.<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F7281044"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Pregnant patients with inherited coagulation disorders may have an increased bleeding risk following invasive procedures, spontaneous miscarriage, termination of pregnancy, and delivery; close surveillance is recommended. Clotting factors should be monitored at the first antenatal visit, once or twice during the third trimester, prior to surgical or invasive procedures, and at delivery. Although factor IX levels remain stable during pregnancy, factor IX replacement is recommended if concentrations are &lt;50 units/dL and any of the following occur: need for invasive procedures (including delivery), spontaneous miscarriage, insertion and removal of epidural catheters, or active bleeding. Hemostatic factor IX concentrations should be maintained for at least 3 to 5 days following invasive procedures or postpartum. If replacement with a factor IX concentrate is indicated to increase factor IX during pregnancy, a recombinant product is preferred. In addition, the use of factor IX concentrates that also contain factors II, VII, IX, and X (also known as PCCs) are rarely used; pure factor IX concentrations are preferred (NHF 2017; RCOG [Pavord 2017]; WFH [Srivastava 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Factor II concentrations do not increase during pregnancy. In women with severe factor II deficiency, PCCs may be administered if factor II activity is &lt; 0.2 IU/mL with significant bleeding, during labor, or prior to cesarean delivery. Patients treated with PCCs prior to pregnancy may continue use. Factor X concentrations may increase during pregnancy; however, patients with severe factor X deficiency remain at risk for bleeding. In addition, treatment may be needed if concentrations are &lt;30 units/dL at term or prior to procedure. Hemostatic concentrations should be maintained for at least 3 days following procedures or postpartum. PCCs may be used for severe factor X deficiency in pregnancy (RCOG [Pavord 2017]).</p></div>
<div class="block mopp drugH1Div" id="F53566849"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Levels of factors II, IX, and X; signs/symptoms of hypersensitivity reactions and bleeding; hemoglobin, hematocrit; screen for factor IX inhibitors by measuring inhibitor titers (children: Every 3-12 months or 10-20 exposure days)   </p></div>
<div class="block rerp drugH1Div" id="F53566360"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Patients with severe hemophilia will have factor IX levels &lt;1%, often undetectable. Moderate forms of the disease have levels of 1% to 5% while some mild cases may have 5% to 49% of normal factor IX. Plasma concentration is about 4 mg/L.</p></div>
<div class="block pha drugH1Div" id="F169657"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Replaces deficient clotting factor including factor X; hemophilia B, or Christmas disease, is an X-linked recessively inherited disorder of blood coagulation characterized by insufficient or abnormal synthesis of the clotting protein factor IX. Factor IX is a vitamin K-dependent coagulation factor which is synthesized in the liver. Factor IX is activated by factor XIa in the intrinsic coagulation pathway. Activated factor IX (IXa), in combination with factor VII:C, activates factor X to Xa, resulting ultimately in the conversion of prothrombin to thrombin and the formation of a fibrin clot. The infusion of exogenous factor IX to replace the deficiency present in hemophilia B temporarily restores hemostasis.</p></div>
<div class="block phk drugH1Div" id="F169673"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;text-align:justify;display:inline">Half-life elimination: IX component: ~19 to 25 hours</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539858"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Prothromplex total</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Prothromplex total</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Prothromplex nf</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Prothromplex total</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Prothromplex total</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Prothromplex total</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Profilnine</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Prothromplex nf</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-15516194">
<a name="15516194"></a>Baker RI, Coughlin PB, Gallus AS, et al, “Warfarin Reversal: Consensus Guidelines, on Behalf of the Australasian Society of Thrombosis and Haemostasis,” <i>Med J Aust,</i> 2004, 181(9):492-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-pediatric-drug-information/abstract-text/15516194/pubmed" id="15516194" target="_blank">15516194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22101176">
<a name="22101176"></a>Chi C and Kadir RA, "Inherited Bleeding Disorders in Pregnancy," <i>Best Pract Res Clin Obstet Gynaecol</i>, 2012, 26(1):103-17.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-pediatric-drug-information/abstract-text/22101176/pubmed" id="22101176" target="_blank">22101176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20514955">
<a name="20514955"></a>Chong CT, Lew TWK, Kuperan P, et al, “Rapid Reversal of Coagulopathy in Warfarin-Related Intracranial Haemorrhages With Prothrombin Complex Concentrates,” <i>Anaesth Intensive Care</i>, 2010, 38(3):474-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-pediatric-drug-information/abstract-text/20514955/pubmed" id="20514955" target="_blank">20514955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22556194">
<a name="22556194"></a>Dowlatshahi D, Butcher KS, Asdaghi N, et al; Canadian PCC Registry (CanPro) Investigators. Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. <i>Stroke</i>. 2012;43(7):1812-1817.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-pediatric-drug-information/abstract-text/22556194/pubmed" id="22556194" target="_blank">22556194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24671832">
<a name="24671832"></a>Frontera JA, Gordon E, Zach V, Jovine M, Uchino K, Hussain MS, Aledort L. Reversal of coagulopathy using prothrombin complex concentrates is associated with improved outcome compared to fresh frozen plasma in warfarin-associated intracranial hemorrhage. <i>Neurocrit Care</i>. 2014;21(3):397-406.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-pediatric-drug-information/abstract-text/24671832/pubmed" id="24671832" target="_blank">24671832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26714677">
<a name="26714677"></a>Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care</i>. 2016;24(1):6-46. doi: 10.1007/s12028-015-0222-x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-pediatric-drug-information/abstract-text/26714677/pubmed" id="26714677" target="_blank">26714677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315257">
<a name="22315257"></a>Guyatt GH, Akl EA, Crowther M, et al, “Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-pediatric-drug-information/abstract-text/22315257/pubmed" id="22315257" target="_blank">22315257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26324838">
<a name="26324838"></a>Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i>. 2015;17(10):1467-1507. doi: 10.1093/europace/euv309.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-pediatric-drug-information/abstract-text/26324838/pubmed" id="26324838" target="_blank">26324838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10499902">
<a name="10499902"></a>Hellstern P, Halbmayer WM, Köhler M, et al, “Prothrombin Complex Concentrates: Indications, Contraindications, and Risks: A Task Force Summary,” <i>Thromb Res</i>, 1999, 95(4 Suppl 1):3-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-pediatric-drug-information/abstract-text/10499902/pubmed" id="10499902" target="_blank">10499902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19210325">
<a name="19210325"></a>Holland L, Warkentin TE, Refaai M, et al, “Suboptimal Effect of a Three-Factor Prothrombin Complex Concentrate (Profilnine-SD) in Correcting Supratherapeutic International Normalized Ratio Due to Warfarin Overdose,” <i>Transfusion</i>, 2009, 49(6):1171-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-pediatric-drug-information/abstract-text/19210325/pubmed" id="19210325" target="_blank">19210325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19298378">
<a name="19298378"></a>Kadir R, Chi C, and Bolton-Maggs P, "Pregnancy and Rare Bleeding Disorders," <i>Haemophilia</i>, 2009, 15(5):990-1005.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-pediatric-drug-information/abstract-text/19298378/pubmed" id="19298378" target="_blank">19298378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16834731">
<a name="16834731"></a>Lee CA, Chi C, Pavord SR, et al, "The Obstetric and Gynaecological Management of Women With Inherited Bleeding Disorders-Review With Guidelines Produced by a Taskforce of UK Haemophilia Centre Doctors' Organization," <i>Haemophilia</i>, 2006, 12(4):301-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-pediatric-drug-information/abstract-text/16834731/pubmed" id="16834731" target="_blank">16834731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15205640">
<a name="15205640"></a>Lee JW, “Von Willebrand Disease, Hemophilia A and B, and Other Factor Deficiencies,” <i>Int Anesthesiol Clin</i>, 2004, 42(3):59-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-pediatric-drug-information/abstract-text/15205640/pubmed" id="15205640" target="_blank">15205640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20011645">
<a name="20011645"></a>Liumbruno G, Bennardello F, Lattanzio A, et al, “Recommendations for the Use of Antithrombin Concentrates and Prothrombin Complex Concentrates,” <i>Blood Transfus</i>, 2009, 7(4):325-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-pediatric-drug-information/abstract-text/20011645/pubmed" id="20011645" target="_blank">20011645</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Lusher JM, “Thrombogenicity Associated With Factor IX Complex Concentrates,” <i>Semin Hematol</i>, 1991, 28(3 Suppl 6):3-5.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11529844">
<a name="11529844"></a>Makris M and Watson HG, “The Management of Coumarin-Induced Over-Anticoagulation Annotation,” <i>Br J Haematol</i>, 2001, 114(2):271-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-pediatric-drug-information/abstract-text/11529844/pubmed" id="11529844" target="_blank">11529844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9065997">
<a name="9065997"></a>Makris M, Greaves M, Phillips WS, et al, “Emergency Oral Anticoagulant Reversal: The Relative Efficacy of Infusions of Fresh Frozen Plasma and Clotting Factor Concentrate on Correction of the Coagulopathy,” <i>Thromb Haemost</i>, 1997, 77(3):477-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-pediatric-drug-information/abstract-text/9065997/pubmed" id="9065997" target="_blank">9065997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21557810">
<a name="21557810"></a>Masotti L, Di Napoli M, Godoy DA, et al, “The Practical Management of Intracerebral Hemorrhage Associated With Oral Anticoagulant Therapy,” <i>Int Stroke J</i>, 2011, 6(3):228-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-pediatric-drug-information/abstract-text/21557810/pubmed" id="21557810" target="_blank">21557810</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  National Hemophilia Foundation (NHF). Medical and Scientific Advisory Council (MASAC) guidelines for perinatal management of women with bleeding disorders and carriers of hemophilia A and B (MASAC document 251). https://www.hemophilia.org/node/3660. Published September 17, 2017. Accessed June 7, 2018.</div>
</li>
<li>
<div class="reference">
                  National Hemophilia Foundation, “Guidelines for Emergency Department Management of Individuals With Hemophilia,” 2006. Available at http://www.hemophilia.org/NHFWeb/Resource/StaticPages/menu0/menu5/menu57/175.pdf
                  </div>
</li>
<li>
<div class="reference">
                  National Hemophilia Foundation, “MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders,” 2010. Available at http://www.hemophilia.org/NHFWeb/Resource/StaticPages/menu0/menu5/menu57/masac190.pdf
                  </div>
</li>
<li>
<div class="reference">
                  National Hemophilia Foundation, “MASAC Recommendations Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding),” 2007. Available at http://www.hemophilia.org/NHFWeb/Resource/StaticPages/menu0/menu5/menu57/masac179.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24589852">
<a name="24589852"></a>Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-pediatric-drug-information/abstract-text/24589852/pubmed" id="24589852" target="_blank">24589852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28447403">
<a name="28447403"></a>Pavord S, Rayment R, Madan B, et al; for the Royal College of Obstetricians and Gynaecologists. Management of inherited bleeding disorders in pregnancy: Green-top Guideline No. 71 (joint with UKHCDO). <i>BJOG</i>. 2017;124(8):e193–e263. doi: 10.1111/1471-0528.14592.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-pediatric-drug-information/abstract-text/28447403/pubmed" id="28447403" target="_blank">28447403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11849221">
<a name="11849221"></a>Preston FE, Laidlaw ST, Sampson B, et al, “Rapid Reversal of Oral Anticoagulation With Warfarin by a Prothrombin Complex Concentrate (Beriplex): Efficacy and Safety in 42 Patients,” <i>Br J Haematol</i>, 2002, 116(3):619-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-pediatric-drug-information/abstract-text/11849221/pubmed" id="11849221" target="_blank">11849221</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Profilnine (factor IX complex) [prescribing information]. Los Angeles, CA: Grifols Biologicals LLC; March 2021.</div>
</li>
<li>
<div class="reference">
                  Shord SS and Lindley CM, “Coagulation Products and Their Uses,” <i>Am J Health Syst Pharm</i>, 2000, 57(15):1403-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-pediatric-drug-information/abstract-text/ 10938981 /pubmed" id=" 10938981 " target="_blank"> 10938981 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22776238">
<a name="22776238"></a>Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al; for the World Federation of Hemophilia (WFH). Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1-e47. doi:10.1111/j.1365-2516.2012.02909.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-pediatric-drug-information/abstract-text/22776238/pubmed" id="22776238" target="_blank">22776238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32744769">
<a name="32744769"></a>Srivastava A, Santagostino E, Dougall A, et al; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia, 3rd edition. <i>Haemophilia</i>. 2020;26(suppl 6):1-158. doi:10.1111/hae.14046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-pediatric-drug-information/abstract-text/32744769/pubmed" id="32744769" target="_blank">32744769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22811449">
<a name="22811449"></a>Switzer JA, Rocker J, Mohorn P, et al. Clinical experience with three-factor prothrombin complex concentrate to reverse warfarin anticoagulation in intracranial hemorrhage. <i>Stroke</i>. 2012;43(9):2500-2502.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-pediatric-drug-information/abstract-text/22811449/pubmed" id="22811449" target="_blank">22811449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19181420">
<a name="19181420"></a>Warren O and Simon B. “Massive, Fatal, Intracardiac Thrombosis Associated with Prothrombin Complex Concentrate,” <i>Ann Emerg Med</i>, 2009, 53(6):758-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-pediatric-drug-information/abstract-text/19181420/pubmed" id="19181420" target="_blank">19181420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15792675">
<a name="15792675"></a>Yasaka M, Sakata T, Naritomi H, et al, “Optimal Dose of Prothrombin Complex Concentrate for Acute Reversal of Oral Anticoagulation,” <i>Thromb Res</i>, 2005, 115(6):455-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-pediatric-drug-information/abstract-text/15792675/pubmed" id="15792675" target="_blank">15792675</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13293 Version 176.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
